Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Neuberg, Donna  [Clear All Filters]
2024
Takahashi T, Watkins B, Bratrude B, Neuberg D, Hebert K, Betz K, Yu A, Choi SW, Davis J, Duncan C, et al. The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities. Transplant Cell Ther. 2024.
2023
Penter L, Liu Y, Wolff JO, Yang L, Taing L, Jhaveri A, Southard J, Patel M, Cullen N, Pfaff KLindahl, et al. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023.
2022
Shimony S, Liu Y, Valtis YK, Paolino JD, Place AE, Brunner AM, Weeks LD, Silverman LB, Vrooman LM, Neuberg D, et al. Nelarabine Combination Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Lymphoma/Leukemia. Blood Adv. 2022.
2021
Penter L, Gohil SHarish, Huang T, Thrash EM, Schmidt D, Li S, Severgnini M, Neuberg D, F Hodi S, Livak KJ, et al. Coevolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. Blood Adv. 2021.
2014
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, R Lindsley C, Mermel CH, Burtt N, Chavez A, et al. Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. N Engl J Med. 2014.
Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, Stevenson K, Sougnez C, Wang L, Li S, et al. Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia. Cancer Cell. 2014;26(6):813-825.
2013
Brown JR, Messmer BT, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, Lacasce AS, Armand P, Jacobsen E, et al. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia / small lymphocytic lymphoma. Haematologica. 2013.